Phase 3 Head and Neck Cancer Trial, Recruiting NCT06030440 Sponsor: University of Erlangen-Nürnberg Medical School Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT06030440
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of cancer (squamous cell carcinoma) affecting the mouth, voice box, or throat area, confirmed by a tissue sample — with some exceptions for very early voice box cancers (confirm with trial site)
  • You have already had surgery to remove the main tumor and nearby lymph nodes, performed in a specific standardized way
  • Your doctors have recommended radiation therapy (with or without chemotherapy) after your surgery
  • Any cancerous lymph nodes found are smaller than 6cm in size
  • Cancerous lymph nodes are only found in up to 3 lymph node regions in the neck
  • The cancer has not spread to other parts of the body
  • You are 18 years of age or older (there is no upper age limit)
  • You are generally well enough to carry out some daily activities (confirm with trial site what this means for you)
  • You have read and understood what the trial involves and are able to follow the trial's instructions
  • You have signed the trial's consent form before starting any trial-related treatment
  • Your radiation therapy will start at least 6 weeks after your last cancer-related surgery

Who may not be able to join:

  • Your surgery was unable to remove all visible tumor tissue
  • Your cancer has spread to other parts of the body
  • There are signs the cancer has come back between your surgery and the planned start of radiation therapy
  • Cancerous lymph nodes are found in more than 3 lymph node regions in the neck
  • You are currently pregnant or breastfeeding
  • You are able to have children but are unwilling to use highly effective contraception during the treatment period
  • You have any condition that might make it difficult for you to follow the trial's schedule or requirements
  • You are currently taking part in another clinical treatment trial
  • You have had any previous cancer treatment other than surgery for this cancer — such as radiotherapy to the head and neck area, or chemotherapy/immunotherapy before surgery
  • You are unable to have both MRI and CT scans with contrast dye (for example, due to allergies or a pacemaker) (confirm with trial site)
  • You had a neck dissection or head and neck surgery more than 2 months before starting radiation therapy that may have affected the lymph drainage in the area (confirm with trial site)
  • You have had another type of cancer in the past, unless it was successfully treated with no signs of disease for at least 5 years, or was a certain type of non-aggressive skin cancer with no signs of disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sarina Müller, PD, Universitätsklinikum Erlangen, HNO

Phone: +49913185

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Erlangen-Nürnberg Medical School
Registry
ClinicalTrials.gov
Start date
26 January 2024
Est. completion
1 December 2031

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Phase II: 1-year PEG feeding tube dependence rate; Phase III: Time to local relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov